Cytek (CTKB) Q4 2025 earnings review
Record Top-Line Recovery Masked by Profitability Collapse
Cytek delivered a record $62.1M in Q4 revenue, marking an 8% YoY increase and officially reversing the severe top-line contraction seen early in 2025. Demand in the US and EMEA recovered, and recurring revenues (services/reagents) surged 21% for the year. However, the bottom line is a disaster. Adjusted gross margins compressed 600 bps YoY, and operating expenses ballooned 25.5%, crushing operating income from a $3.0M profit last year to a $5.6M loss. A massive $38.1M non-cash tax valuation allowance further torpedoed Net Income to negative $44.1M. While management struck a victorious tone about revenue momentum, their lackluster 2026 guidance (2-5% growth) suggests Q4 was more of a year-end budget flush than a structural acceleration.
🐂 Bull Case
After a brutal start to 2025 (Q1 down 7.6%), revenue growth accelerated sequentially through the year, culminating in a record $62.1M quarter and +8% YoY growth in Q4. EMEA and US instrument demand are finally stabilizing.
Service and reagent revenues grew 21% YoY, now comprising 34% of total revenue. This high-margin, sticky revenue stream fundamentally de-risks the company's historical reliance on volatile capital equipment purchases.
🐻 Bear Case
Adjusted Gross Margin fell from 61% in 24Q4 to 55% in 25Q4. Despite record revenues, the company is demonstrating negative operating leverage, indicating weak pricing power or structurally higher manufacturing/service costs.
Operating expenses jumped 25.5% in Q4, driven entirely by a $7.3M spike in General & Administrative costs (headcount, sales commissions, and patent litigation). This reversed a $3.0M operating profit in 24Q4 to a $5.6M operating loss in 25Q4.
⚖️ Verdict: 🔴
Bearish. Generating record quarterly revenue but delivering a $5.6M operating loss (and massive Net Loss) due to margin compression and G&A bloat is a major red flag. Cytek is selling more but making significantly less.
Key Themes
Recurring Revenues Drive the Business Model Shift
The transition to a razor-and-blade model is accelerating. Total recurring revenue (services and reagents) grew 21% in 2025, reaching 34% of total revenue. This provides a crucial buffer against the highly cyclical macro environment that suppressed instrument sales earlier in the year.
Massive Tax Valuation Allowance Signals Profitability Doubts
The company recorded a $38.1M non-cash valuation allowance against deferred tax assets in Q4 (totaling $33.1M for the full year net impact). Companies typically do this when there is 'uncertainty of realizing the associated future tax benefits'—in plain English, auditors and management do not expect sufficient GAAP taxable income in the near future to utilize these assets.
Runaway General & Administrative Expenses
G&A is out of control. It surged 36.7% for the full year to $58.9M. In Q4 alone, it jumped by $7.3M YoY. Management blames higher patent litigation expenses, compensation, and software costs. Until litigation is resolved and Cytek demonstrates cost discipline, operating margins will remain suppressed.
Instrument Placements and Innovation Cycle
The installed base expanded by 630 instruments in 2025, reaching 3,664. Cytek is actively upgrading its hardware cycle with the launch of the Aurora Evo system (targeting high-throughput, automated large pharma workflows) and the Muse Micro analyzer, which won a 2025 Biotech Breakthrough Award. The flagship Aurora CS system saw unit placements grow 22%.
Guidance Contradicts Management's Bullish Tone
CEO Wenbin Jiang praised the 'broad-based execution' that 'positions us well for 2026.' However, 2026 revenue guidance is set at $205-$212M, representing anemic 2% to 5% YoY growth. This is a sharp deceleration from the 8% growth achieved in Q4, indicating management expects the macro funding environment (or competitive pressures) to cap top-line expansion.
Other KPIs
Reversing. Down drastically from $12.5M in 24Q4. While it recovered sequentially from the -$3.3M loss in 25Q1, the YoY collapse highlights how poorly revenue growth is translating to cash generation due to weaker gross margins and bloated operating expenses.
Stable sequentially ($261.7M in Q3), but down $16.4M for the full year. The cash burn was primarily driven by the company opportunistically repurchasing 3.3 million shares for $15.1 million during 2025. The balance sheet remains highly liquid and debt-free.
Guidance
Decelerating. The midpoint of $208.5M implies +3.5% YoY growth. While it's an improvement over the +1% growth seen in the full year 2025, it is a significant step down from the 8% exit velocity of Q4 2025. This assumes no change in current foreign currency rates or 2025 US tariff policy.
Key Questions
Litigation Cost Visibility
G&A expenses surged nearly 37% this year, largely due to patent litigation. What is the timeline for resolving these legal disputes, and what is the normalized G&A run-rate once they conclude?
Gross Margin Bridge
Adjusted gross margins have structurally dropped from the 60%+ range down to 55%. How much of this 500-600 bps compression is driven by permanent pricing/mix shifts versus temporary manufacturing absorption or tariff issues?
2026 Guidance Conservatism
You exited Q4 with 8% revenue growth and noted improving demand in the US and EMEA. Yet, your 2026 guidance implies just 2-5% growth. Are you anticipating a give-back of Q4 budget-flush orders, or are you just being highly conservative regarding academic funding visibility?